Vande Woude / Klein Advances in Cancer Research

1. Auflage 2011
ISBN: 978-0-08-046448-0
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band Volume 95, 376 Seiten, Web PDF

Reihe: Advances in Cancer Research

The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents outstanding and original reviews on a variety of topics including NY-ESO-1: review of an immunogenic tumor antigen; Order, disorder, death: lessons from a superorganism; Control of differentiation in progression of epithelial tumors; Cancer vaccines: preclinical studies and novel strategies; Clinical results of vaccine therapy for cancer: learning from history for improving the future; Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell based cancer vaccines; NK cell receptors as tools in cancer immunotherapy; Innate immune recognition and suppression of tumors; Inhibitors of the HSP90 molecular chaperone: current status.

Autoren/Hrsg.

Vande Woude, George F.

Klein, George

Inhaltsverzeichnis

1;Cover Page;1
2;Contents;6
3;Contributors to Volume 95;10
4;Chapter 1: NY-ESO-1: Review of an Immunogenic Tumor Antigen;13
4.1;I. Identity Card: Background Information for NY-ESO-1;14
4.2;II. Package Insert: Therapeutic Potential of NY-ESO-1;17
4.3;III. Concluding Remarks;34
4.4;Acknowledgments;34
4.5;References;34
5;Chapter 2: Order, Disorder, Death: Lessons from a Superorganism;43
5.1;I. Order in Living Organisms;44
5.2;II. Superorganisms;44
5.3;III. Honeybee Society;45
5.4;IV. Regulation of Differentiation, Growth, and Homeostasis;49
5.5;V. Regulation of Death;54
5.6;VI. Order, Disorder, and Disease;58
5.7;VII. Conclusions;63
5.8;Acknowledgments;65
5.9;References;65
6;Chapter 3: Control of Differentiation in Progression of Epithelial Tumors;73
6.1;I. Introduction;74
6.2;II. Normal Epitheliocyte;75
6.3;III. Microenvironmental Control of Transformed Cells;87
6.4;IV. Concluding Remarks and Further Perspective;109
6.5;Acknowledgments;111
6.6;References;112
7;Chapter 4: Cancer Vaccines: Preclinical Studies and Novel Strategies;127
7.1;I. Introduction;128
7.2;II. Types of Targets for Vaccine Therapy;128
7.3;III. Vaccine Strategies;129
7.4;IV. Biological Adjuvants;137
7.5;V. Multimodal Therapies;138
7.6;VI. Next-Generation Vaccine Design and Delivery;142
7.7;VII. Challenges in Cancer Vaccine Design;146
7.8;VIII. Conclusions;147
7.9;Acknowledgments;147
7.10;References;147
8;Chapter 5: Clinical Results of Vaccine Therapy for Cancer: Learning from History for Improving the Future;159
8.1;I. Introduction;160
8.2;II. Vaccine Trials in B-Cell Malignancies;161
8.3;III. B-Cell Chronic Lymphocytic Leukemia;164
8.4;IV. Multiple Myeloma;164
8.5;V. Vaccine Trials in Solid Tumors;169
8.6;VI. Incorporation of Vaccine Treatment into Chemotherapy Regimens;194
8.7;VII. Relevance of Regulatory T-Cells for Vaccine Therapy of Cancer;195
8.8;VIII. Immunological Adjuvants for Cancer Vaccines;198
8.9;IX. Conclusions;199
8.10;References;201
9;Chapter 6: Immunodominance and Immunodomination: Critical Factors in Developing Effective CD8+ T-Cell-Based Cancer Vaccines;215
9.1;I. Introduction;216
9.2;II. The Phenomenon: Immunodominance;218
9.3;III. Theoretical Contributions of Antigen Processing and Presentation to Immunodominance;220
9.4;IV. Immunodomination and its Possible Mechanisms;226
9.5;V. Immunodominance is Susceptible to Viral Escape;237
9.6;VI. Immunodominance in Antitumor Responses and Tumor Escape;239
9.7;VII. Immunodominance and Cancer Vaccines;240
9.8;VIII. Conclusions;245
9.9;Acknowledgments;246
9.10;References;246
10;Chapter 7: NK Cell Receptors as Tools in Cancer Immunotherapy;261
10.1;I. Introduction;262
10.2;II. NK Cell Recognition of Tumor Cells;263
10.3;III. NK Cell Receptors;265
10.4;IV. Blocking Inhibitory Receptors to Activate Immunity;275
10.5;V. Use of Activating NK Receptors or Ligands in Cancer Immunotherapy;280
10.6;VI. Chimeric NK Cell Receptors as Cancer Immunotherapy;284
10.7;VII. Conclusions;289
10.8;Acknowledgments;290
10.9;References;290
11;Chapter 8: Innate Immune Recognition and Suppression of Tumors;305
11.1;I. Tumor Immune Surveillance: An Introduction;306
11.2;II. The Immune System is an Extrinsic Tumor Suppressor;306
11.3;III. Synposis of an Effective Immune Response;307
11.4;IV. Innate and Adaptive Immune Cells that Control Tumors;309
11.5;V. Immune Molecules that Recognize and Control Cancer;314
11.6;VI. NKG2D Triggers Tumor Cell Killing;319
11.7;VII. Conclusions;323
11.8;Acknowledgments;324
11.9;References;324
12;Chapter 9: Inhibitors of the HSP90 Molecular Chaperone: Current Status;335
12.1;I. Introduction;336
12.2;II. HSP90 Inhibitors;339
12.3;III. Clinical Evaluation of 17-AAG and 17-DMAG;351
12.4;IV. Concluding Remarks;352
12.5;Acknowledgments;354
12.6;References;354
13;Index;361